Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

作     者：Zhenyi Niu Runsen Jin Yan Zhang Hecheng Li 

作者机构：Department of Thoracic SurgeryRuijin HospitalShanghai Jiao Tong University School of Medicine197 Ruijin 2nd RoadShanghaiChina Department of Immunology and MicrobiologyShanghai Jiao Tong University School of Medicine280 South Chongqing RoadShanghaiChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2022年第7卷第11期

页      面：4090-4117页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：National Key Research and Development Program of China(2021YFC2500903,2021YFC2500905) Natural Science Foundation of Shanghai(22ZR1439200) National Natural Science Foundation of China(82072557,81871882) Shanghai Municipal Commission of Health and Family Planning Outstanding Academic Leaders Training Program(2017BR055) Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant(20172005) 

主　　题：therapies squamous targeted 

摘      要：Lung cancer is the leading cause of cancer-related death across the *** lung adenocarcinoma,patients with lung squamous cell carcinoma(LSCC)have not benefitted from targeted *** immunotherapy has significantly improved cancer patients’outcomes,the relatively low response rate and severe adverse events hinder the clinical application of this promising treatment in ***,it is of vital importance to have a better understanding of the mechanisms underlying the pathogenesis of LSCC as well as the inner connection among different signaling pathways,which will surely provide opportunities for more effective therapeutic interventions for *** this review,new insights were given about classical signaling pathways which have been proved in other cancer types but not in LSCC,including PI3K signaling pathway,VEGF/VEGFR signaling,and CDK4/6 *** signaling pathways which may have therapeutic potentials in LSCC were also discussed,including the FGFR1 pathway,EGFR pathway,and KEAP1/NRF2 ***,chromosome 3q,which harbors two key squamous differentiation markers SOX2 and TP63 is discussed as well as its related potential therapeutic *** also provided some progress of LSCC in epigenetic therapies and immune checkpoints blockade(ICB)***,we outlined some combination strategies of ICB therapies and other targeted ***,prospects and challenges were given related to the exploration and application of novel therapeutic strategies for LSCC.